Potentiation of a functional autoantibody in narcolepsy by a cholinesterase inhibitor

Laboratory Investigation

Volumn 89, Issue 12, 2009, Pages 1332-1339

  Jackson, Michael W ^a   Spencer, Nicolas J ^a   Reed, Joanne H ^a   Smith, Anthony J F ^a   Gordon, Tom P ^a  

^a FLINDERS UNIVERSITY   (Australia)

Author keywords

Autoantibody; Autoimmunity; Myenteric; Narcolepsy; Neostigmine; Neuron

Indexed keywords

ATROPINE; AUTOANTIBODY; CHOLINESTERASE INHIBITOR; IMMUNOGLOBULIN G; NEOSTIGMINE; TETRODOTOXIN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOASSAY; CASE REPORT; CATAPLEXY; COLON; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HUMAN; MALE; MIGRATING MYOELECTRIC COMPLEX; MOTONEURON; MOTOR ACTIVITY; MOUSE; MUSCLE TONE; NARCOLEPSY; NONHUMAN; PRIORITY JOURNAL; SMOOTH MUSCLE CONTRACTION; SMOOTH MUSCLE TONE;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ATROPINE; AUTOANTIBODIES; CASE-CONTROL STUDIES; CHOLINESTERASE INHIBITORS; COLON; ENTERIC NERVOUS SYSTEM; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; MUSCARINIC ANTAGONISTS; MUSCLE TONUS; MUSCLE, SMOOTH; MYOELECTRIC COMPLEX, MIGRATING; NARCOLEPSY; NEOSTIGMINE; SODIUM CHANNEL BLOCKERS; SYNAPTIC TRANSMISSION; TETRODOTOXIN; YOUNG ADULT;

EID: 70549106257     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2009.108     Document Type: Article

References (35)

1. Overeem S, Mignot E, van Dijk JG, et al. Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives. J Clin Neurophysiol 2001;18:78-105.
2. Scammell TE. The neurobiology, diagnosis, and treatment of narcolepsy. Ann Neurol 2003;53:154-166.
3. Nishino S, Ripley B, Overeem S, et al. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000;355:39-40.
4. Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000;6:991-997.
5. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000;27:469-474.
6. Rogers AE, Meehan J, Guilleminault C, et al. HLA DR15 (DR2) and DQB1*0602 typing studies in 188 narcoleptic patients with cataplexy. Neurology 1997;48:1550-1556.
7. Mignot E, Lin L, Rogers W, et al. Complex HLA-DR and-DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am J Hum Genet 2001;68:686-699.
8. Hallmayer J, Faraco J, Lin L, et al. Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nature Genetics print copy in press May 2009. Available from: URL: www.nature.com/ng/journal/vaop/ ncurrent/abs/ng.372. html.
9. Black III JL. Narcolepsy: a review of evidence for autoimmune diathesis. Int Rev Psychiatry 2005;17:461-469.
10. Scammell TE. The frustrating and mostly fruitless search for an autoimmune cause of narcolepsy. Sleep 2006;29:601-602.
11. Overeem S, Black III JL, Lammers GJ. Narcolepsy: immunological aspects. Sleep Med Rev 2008;12:95-107.
12. Honda M, Eriksson KS, Zhang S, et al. IGFBP3 colocalizes with and regulates hypocretin (orexin). PLoS ONE 2009;4:e4254.
13. Miyagawa T, Kawashima M, Nishida N, et al. Variant between CPT1B and CHKB associated with susceptibility to narcolepsy. Nat Genet 2008;40:1324-1328.
14. Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol 1997;52:27-78.
15. Guilleminault C, Heinzer R, Mignot E, et al. Investigations into the neurologic basis of narcolepsy. Neurology 1998;50:S8-S15.
16. Jackson MW, Gordon TP, Waterman SA. Disruption of intestinal motility by a calcium channel-stimulating autoantibody in type 1 diabetes. Gastroenterology 2004;126:819-828.
17. Wang F, Jackson MW, Maughan V, et al. Passive transfer of Sjogren's syndrome IgG produces the pathophysiology of overactive bladder. Arthritis Rheum 2004;50:3637-3645.
18. Waterman SA, Jackson MW, Gordon TP. Functional effects of autoantibodies. In: Mackay IR, Rose NR (eds). The Autoimmune Diseases, 4th edn. Elsevier: Sydney, 2006, pp 217-236.
19. Wan EC, Gordon TP, Jackson MW. Autoantibody-mediated bladder dysfunction in type 1 diabetes. Scand J Immunol 2007;65:70-75.
20. Wan EC, Gordon TP, Jackson MW. Autoantibodies to calcium channels in type 1 diabetes mediate autonomic dysfunction by different mechanisms in colon and bladder and are neutralized by antiidiotypic antibodies. J Autoimmun 2008;31:166-172.
21. Jackson MW, Reed JH, Smith AJ, et al. An autoantibody in narcolepsy disrupts colonic migrating motor complexes. J Neurosci 2008;28:13303-13309.
22. Cestele S, Catterall WA. Molecular mechanisms of neurotoxin action on voltage-gated sodium channels. Biochimie 2000;82:883-892.
23. Fida R, Lyster DJ, Bywater RA, et al. Colonic migrating motor complexes (CMMCs) in the isolated mouse colon. Neurogastroenterol Motil 1997;9:99-107.
24. Park K, Gordon TP, Jackson MW. Functional autoantibodies in primary Sjogren's syndrome disrupt gastrointestinal tract motility by targeting the muscarinic 3 receptor. American College of Rheumatology. Arthritis Rheum, San Francisco 2008, pp S795.
25. Steinbuch M, Audran R. The isolation of IgG from mammalian sera with the aid of caprylic acid. Arch Biochem Biophys 1969;134:279-284.
26. Cavill D, Waterman SA, Gordon TP. Antiidiotypic antibodies neutralize autoantibodies that inhibit cholinergic neurotransmission. Arthritis Rheum 2003;48:3597-3602.
27. Spencer NJ, Hennig GW, Dickson E, et al. Synchronization of enteric neuronal firing during the murine colonic MMC. J Physiol 2005;564:829-847.
28. Kohn LD, Harli H. Thyrotropin receptor autoantibodies (TSHRAbs): epitopes, origins and clinical significance. Autoimmunity 2003;36: 331-337.
29. Smith AJ, Jackson MW, Neufing P, et al. A functional autoantibody in narcolepsy. Lancet 2004;364:2122-2124.
30. Spencer NJ. Control of migrating motor activity in the colon. Curr Opin Pharmacol 2001;1:604-610.
31. Smith DO. Acetylcholine storage, release and leakage at the neuromuscular junction of mature adult and aged rats. J Physiol 1984;347:161-176.
32. Zagorodnyuk V, Gregory S, Costa M, et al. Spontaneous release of acetylcholine from autonomic nerves in the bladder. Br J Pharmacol 2009;157:607-619.
33. Delashaw Jr JB, Foutz AS, Guilleminault C, et al. Cholinergic mechanisms and cataplexy in dogs. Exp Neurol 1979;66:745-757.
34. Nishino S, Tafti M, Reid MS, et al. Muscle atonia is triggered by cholinergic stimulation of the basal forebrain: implication for the pathophysiology of canine narcolepsy. J Neurosci 1995;15:4806-4814.
35. Reid MS, Tafti M, Geary JN, et al. Cholinergic mechanisms in canine narcolepsy-I. Modulation of cataplexy via local drug administration into the pontine reticular formation. Neuroscience 1994;59:511-522.